Our company is developing nasal sprays containing antibodies that target respiratory viruses in the nasal mucosa. These sprays aim to:
• Fight the initial infection at the gate: which can prevent onward transmission.
• Protect broadly against existing and new viruses.
• Provide universal protection, regardless of an individual’s immune history or comorbidities.
With our products, we fight viruses where they fight us, to prepare us for future endemic and pandemic threats. We have a pipeline of clinical and pre-clinical candidates for influenza and corona viruses.
The company’s founders are biotechnology veterans who founded and built vaccine pioneer Crucell. Leyden Labs has raised $200M from investors including GV, Casdin Capital, F-Prime, SoftBank, and Byers Capital/Brook Byers.
Powered by: BCF Courses BV | Connect with us | Join BioBusiness Summer School | |||
Privacy Policy Terms & Conditions Chamber of Commerce: 75874415 | | REGISTER NOW |
© Copyright 2020 by BCF Courses